Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer (BusinessWire)

Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer

UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck’s HPV/Gardasil Franchise. Ms. Murphy joined Oragenics’ Board of Directors in 2020.

“As a Board Member, Ms. Murphy’s extensive experience in the vaccine industry has provided valuable insight for Oragenics’ corporate and development strategies. Her proven leadership and execution will continue to elevate the potential of the Company and our pipeline programs,” commented Fred Telling, Chairman of Board of Directors. “We are excited to have her strategic vision further implemented serving as President and Chief Executive Officer.”

Learn more about Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer<>
X